Clinical Trial

Liposomal Irinotecan in Combination With Temozolomide and Bevacizumab in Patients With Advanced STS

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is expected to include 24 patients with metastatic or surgically unresectable relapsed/refractory soft tissue sarcoma confirmed by histological evidence, who have received at least one line of systemic treatment previously. The efficacy and safety of liposome irinotecan combined with temozolomide and bevacizumab in the treatment of relapsed/refractory soft tissue sarcoma will be evaluated.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07457775
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Soft Tissue Sarcoma (Excluding GIST)
Enrollment 24 participants
Start Date 2026-03-31
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-09